Initial Study of Human Genetic Contribution to COVID-19 Severity and Susceptibility

Fang Wang[1]*, Shujia Huang[2,3]*, Rongsui Gao[1]*, Yuwen Zhou[2,4]*, Changxiang Lai[1]*, Zhichao Li[2,4]*, Wenjie Xian[1], Xiaobo Qian[2,4], Zhiyu Li[1], Yushan Huang[2,4]，Qiyuan Tang[1], Panhong Liu[2,4], Ruikun Chen[1], Rong Liu[2], Xuan Li[1], Xin Tong[2], Xuan Zhou[1], Yong Bai[2], Gang Duan[1], Tao Zhang[2], Xun Xu[2,5], Jian Wang[2,6], Huanming Yang[2,6], Siyang Liu[2#], Qing He[1#], Xin Jin[2,3#], Lei Liu[1#]

1. The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518112, Guangdong, China
2. BGI-Shenzhen, Shenzhen 518083, Guangdong, China
3. School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong, China
4. BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, Guangdong, China
5. Guangdong Provincial Key Laboratory of Genome Read and Write，BGI-Shenzhen, Shenzhen, 518120，China
6. James D. Watson Institute of Genome Science, 310008 Hangzhou, China

*Those authors contribute equally

Corresponding to any of the followings:

Lei Liu liuleiszsdsrmyy@163.com

Xin Jin jinxin@genomics.cn

Qing He heqingjoe@163.com

Siyang Liu liusiyang@genomics.cn

Abstract

The COVID-19 pandemic has accounted for more than five million infections and hundreds of thousand deaths worldwide in the past six months. The patients demonstrate a great diversity in clinical and laboratory manifestations and disease severity. Nonetheless, little is known about the host genetic contribution to the observed inter-individual phenotypic variability. Here, we report the first host genetic study in China by deeply sequencing and analyzing the 332 COVID-19 patients categorized by varying levels of severity from the Shenzhen Third People's Hospital. Based on a total of 22.2 million genetic variants, we conducted both single-variant and gene-based association tests among the five severity groups including asymptomatic, mild, moderate, severe and critical ill patients after the correction of potential confounding factors. The most significant gene loci associated with severity is located in *TMEM189-UBE2V1* involved in the IL-1 signaling pathway. The p.Val197Met missense variant that affects the stability of the TMPRSS2 protein displays a decreasing allele frequency among the severe patients compared to the mild and the general population. We also identified that the HLA-A*11:01, B*51:01 and C*14:02 alleles significantly predispose the worst outcome of the patients. This initial study of Chinese patients provides a comprehensive view of the genetic difference among the COVID-19 patient groups and highlighted genes and variants that may help guide targeted efforts in containing the outbreak. Limitations and advantages of the study was also reviewed to guide future international efforts on elucidating the genetic architecture of host-pathogen interaction for COVID-19 and other infectious and complex diseases.

Introduction

It has been more than 100 years since the 1918 influenza outbreak killed at least fifty million people worldwide[1]. Now we are facing another pandemic. Since the late December of 2019, the 2019 novel coronavirus diseases (COVID-19) has spread rapidly throughout the world, resulting in more than five million confirmed cases and hundreds of thousands deaths in less than six months[2,3]. The disease was caused by the infection of a novel enveloped RNA betacoronavirus that has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the seventh coronavirus species that causes respiratory disease in humans[4,5]. The virus causes serious respiratory illnesses such as pneumonia, lung failure and even death[6]. Until now, there is no specific therapeutics and vaccine available for its control. Continuing epidemiological and molecular biological study to better understand, treat and prevent COVID-19 are urgently needed.

A characteristic feature of many human infections is that only a proportion of exposed individuals develop clinical disease and for the infected persons, severity varies from person to person[7]. In the COVID-19 outbreak, a high level of inter-individual variability was observed in terms of disease severity and symptomatic presentation. Around 80%-85% of the laboratory confirmed patients were classified as mild (i.e. nonpneumonia and mild pneumonia) while 15%-20% would progress to severe or critical stage with a high probability of

respiratory failure[8–11]. Patients with severe disease had more prominent
laboratory abnormalities including lymphocytopenia and leukopenia than those
with non-severe disease[12,13]. In addition, not all people exposed to SARS-CoV-
2 were infected according to the epidemiological observation of the patients'
close contacts[14,15]. Notably, previous studies have indicated that genetic
background plays an essential role in determining the host responses to
infections by HIV[16–18], HBV[19], HCV[20], influenza[21–24], SARS-CoV[25,26] and
numerous common viruses[27] etc. Those studies highlighted the HLA alleles and
several genes involved in the interferon production and viral replication pathway
and indicates that genetic factors may also play an important role to explain the
inter-individual clinical variability among patients infected by SARS-CoV-2.
Till now, the global genetic community has been actively investigating in
the genetic contribution to COVID-19. A recent twin study in UK suggests a 30%
-50% genetic heritability for self-reported symptoms of COVID-19 and the
predictive disease onset[28], indicating a very strong genetic background
predisposing the COVID-19 patients' clinical manifestation and susceptibility.
An earlier studies comparing the distribution of ABO blood group from 1,775
patients infected with SARS-CoV-2 with 3,694 normal people from Wuhan city
and 23, 386 people from Shenzhen city suggested that blood group A had a
significantly higher risk for COVID-19 (OR=1.20, p=0.02) while blood group O
had the lower risk[29]. Using allele frequency and expression quantitative loci
(eQTL) information of general healthy population from 1000 genome project
and others, a few studies investigate the mutation frequency spectrum in
different populations in candidate genes such as *ACE2* and *TRMPSS2*[30–32].
Genome-wide association test on array data from the UK Biobank participants
with a positive and negative PCR-tests also reveals a few suggestive genes[27].
The COVID-19 host genetics initiative was established to encourage generation,
sharing and meta- analysis of the genome-wide association summary statistics
data around the world[33]. International collaborative efforts are necessary to
elucidate the role of host genetic factors defining the severity and susceptibility
of the SARS-CoV-2 virus pandemic.
Herein, we report the initial genetic study of COVID-19 disease severity
in China by deeply analyzing the association between the genetic variants
present in the patients' genome and their disease progression. We have
recruited 332 hospitalized patients from a designated infectious disease
hospital in Shenzhen City[34]. The patients display varying clinical and laboratory
features and were categorized as asymptomatic, mild, moderate, severe and
critical cases according to the criteria made by the Chinese Center for Disease
Control and Prevention[6]. To maximize the statistical power given the relatively
small hospitalized sample size and for accurate detection of extremely rare
variants, we conducted deep whole genome sequencing (average 46x) for the
patients. Given a fixed samples size, this protocol facilitates the estimation of
genetic effects of rare and loss of function variants in addition to the common
variants that may be potentially contributing to the COVID-19 clinical variability[35].
Based on the 22.2 million variation detected from the patients, we investigated
host factors by conducting both single variant and gene-based genome-wide

association study and by evaluating the difference of allele frequency of the protein truncating variants and HLA alleles among the patient groups. In addition, to explore potential genetic factors that may contributing to genetic susceptibility, we performed joint-calling of the genetic variants of the COVID-19 patients (N=284) and the publicly available Chinse genomes from the 1000 genome project[36] (N=301, ~7x) and 665 selected Chinese genomes from the Chinese Reference Panel Population (manuscript in preparation, ~30x) to explore potential genetic factors that may contribute genetic susceptibility of SARS-CoV-2 infection.

Results
Clinical and laboratory features of the 332 hospitalized COVID-19 patients
The 332 recruited patients with laboratory-confirmation of SARS-COV-2 infection were being quarantined and treated in the Shenzhen Third Hospital. We extracted and analyzed the clinical symptoms, laboratory assessment, recent exposure history of the patients from the hospital's electronic medical records. The 332 patients consist of 48 family members and 284 unrelated individuals.

25 (7.5%), 12 (3.6%), 225 (67.8%), 53 (16.0%) and 17 (5.1%) patients were defined as asymptomatic, mild, moderate, severe and critically severe according to the most severe stage they encountered during the disease course following the Chinese CDC criteria[6] **(Figure 1A)**. The asymptomatic, mild and the moderate groups of patients do not have or have mild pneumonia. The severe patients met any one of the following criteria: respiratory rate (RR) $\geq$ 30/min, blood oxygen saturation $\leq$ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) < 300 mmHg and/or lung infiltrates > 50% within 24-48 hours. A severe patient was classified as critical ill if he/she experienced any one of the following situations: respiratory failure, septic shock and/or multiple organ dysfunction or failure. A broader definition of the mild group includes asymptomatic, mild and moderate patients and of the severe group includes severe and critically severe patients.
The patients' clinical presentations mainly involve fever (70.8%), cough (54.2%), fatigue (23.9%), hoarse voice (17.6%), loss of appetite (16.2%), delirium (15.1%) and less than 10% had experienced diarrhea, chest and abdominal pain, shortness of breath and anosmia **(Figure S1).** More than 50% of the patients have at least one medical comorbidities (e.g., hypertension). Consistent with previous report, the broadly defined severe patients tend to be older (severe average 45 years old vs mild average 58 years old, t-test p=0.03，**Figure 1C**), a longer disease duration (period of time between disease onset and the first negative PCR-test, **Figure 1D**) and shorter exposure time (**Figure S2**) , consist of more males than females (severe 66.7% vs mild 41.3%, χ^2 test p=4.3e-4, **Figure 1E**) and tend to undergo medical comorbidities more frequently (severe 58.8% vs mild 45.1%, χ^2 test p=0.07) (**Figure 1F**).

During hospitalization, a series of sixty four laboratory assessments
including a complete blood count and blood chemical analysis, assessment of
liver function, assessment of renal functions, test of humoral immunity, test of
coagulation, measure of electrolyte and measure of blood gas electrolyte
(**Figure S3**) and a time-series evaluation of T lymphocyte subgroups (**Figure**
S4) were performed for each of the patients to monitor their disease status and
progression. Using a tree-based machine learning prediction model[37], we
computed the local interaction effects of the sixty four laboratory assessment
features as well as three demographic features including age, gender and w/o
medical comorbidities for classification of the patient severity category (**Figure**
S5). The top ten features of greatest importance that contribute to a severer
disease outcome include decreased lymphocyte counts (Tc-Count, T-CELL,
LYMPH#) and platelet counts, evaluated interleukin 6, C-reactive protein and
D-dimer, increased age and decreased A/G and CO2 (**Figure 1B**), consistent
with previous reports[38]. We applied the top twenty features of importance to
assign a severity score for each patient to reflect their disease status (**Figure**
S6).
183

Deep whole genome sequencing and genetic variation

We obtained the whole blood and performed deep whole genome sequencing
for the recruited patients. There is no significant difference for sequencing depth
between the broadly defined mild and severe group (mild 46.26x vs severe
46.71x) (**Figure 2A**). We conducted variation detection and genotyping using
the GATK joint genotyping framework to avoid any potential batch effect derived
from individual variant calling. Bioinformatics analysis and the data quality
control process are described in details in the **Online methods**.
Among the 332 patients, we identified a total of 22.2 million variants
including 17.9 million bi-allelic single nucleotide polymorphism, 1.75 million bi-
allelic small insertions and deletions and 2.49 million multi-allelic variants
(Figure 2B). The average transition/transversion (ts/tv) ratio is 2.12 and the
proportion of heterozygous versus homozygous variants among all the samples
is 1.29, consistent with the expectation[39] and indicates good quality of the
variant calls (**Figure S7**). Particularly, we have identified 398K variants that
result in an alteration of the protein coding sequence (**Figure 2C**). The QC
metrics were detailed in **Table S1**.
Our first question was whether the most vulnerable severe and critical
patients may have a monogenic basis for their demonstration. We investigated
the burden of loss of function variants predicted by the ensemble variant effect
predictor among the patient groups[40]. In total, we have identified 4,891
predicted loss of function variants including 1,860 frameshift, 1,447 stop gained,
505 splice donor and 380 splice acceptor variants among the 332 patients. On
average, each patient possessed 201 predicted loss of function variants in their
genome **(Figure S8).** 261 of those variants are uniquely presented in the
COVID-19 patients (18.6%) and have not been previously reported in the 1000
genome and the gnomAD studies[36,41,42]. Interestingly, the severe and the critical
patients tend to have more loss of function insertions than the asymptomatic,

mild and the moderate groups in a logistic regression taking the number of loss
of function variants as variable and the patients' age, gender, the top five
principle components and effective sequencing depth as covariates (p=0.004)
(**Figure 2D**). When performing a mutation burden test for each of the 16,801
genes that have more than one variant among the 284 unrelated patients, we
didn't identify genes that were enriched in loss of function variants in the severe
and critical patients (**Figure 2E**). On the other hand, we found two heterozygous
loss of function variants located in *MST1R* and *RASA2* that were only present
in the asymptomatic patients (**Figure S9**). The *MST1R* encodes the
macrophage stimulating 1 receptor expressed on the ciliated epithelia of the
mucociliary transport apparatus of the lung and follows an autosomal dominant
inheritance mode for susceptibility to nasopharyngeal carcinoma[43]. Because
those loss of function variants were only present in one patient, we didn't build
up links to the COVID-19 severity.
Particularly, we have inspected the missense and loss of function variants
present in the SARS-CoV-2 S protein host cellular receptor gene *ACE2*, the S
protein primer gene *TMPRSS2* that plays a critical role in controlling the viral
entry into the host cell and other genes that were predicted to be play a role in
the host pathogen interaction network like *SLC6A19, ADAM17, RPS6,*
HNRNPA1, SUMO1, NACA and *BTF3* [44]. The majority of the functional variants
have minor allele frequency less than 1% except for the p.Val197Met missense
variant in *TMPRSS2* (**Figure 2F**). Although not statistically significant, the
p.Val197Met variant (rs12329760) displays a higher allele frequency in the
asymptomatic and mild group compared to the rest of the group (asymptomatic:
0.46, mild: 0.50, moderate: 0.38, severe: 0.39, critical severe: 0.26).
p.Val197Met was previously found to have higher allele frequency in East Asian
(0.31-0.41) and Finnish (0.36) but is less frequently seen in South Asians (0.14-
0.29) and the Europeans (0.17-0.23) (**Figure S10**). By computational protein
modelling, the p.Val197Met TMPRSS2 isoform could decrease the stability of
the TMPRSS2 protein, promote the binding to S-protein and inhibit its binding
with ACE2[44]. The decreasing allele frequency in the severe patient groups is
consistent and supports that the p.Val197Met is related to the disease
outcomes of COVID-19. Other genes didn't contain significant allele frequency
difference among the patient groups (**Figure S11**).
246
Genetic association of common and rare variants with COVID-19 severity
To further investigate genetic effects for the patient severity, we performed
genome-wide single variant association test and sequence kernel association
test (SKAT) analysis of three traits implicating patient severity. We defined the
first trait as a dichotomous classification of the broadly defined "mild group"
(N=262) that consists of the asymptomatic, mild and moderate patients and the
"severe group" that consists of the severe and critical ill patients (N=70). We
defined the second trait as a quantitative measurement of the severity level
trained from the demographic features such as age, gender and the sixty-four
laboratory assessments (N=332) (**Figure S5-6**). We used the disease duration
from the electronic health records as the third trait which corresponds to the

time duration between the complained disease onset and the first laboratory
confirmed PCR-test negative outcome (N=233) (**Figure 1D**). Power analysis
indicates that given 80% statistical power, we will be able to identify
associations between genotypes and phenotypes for variants with minor allele
frequency greater than 0.2 and with a relative genetic risk contribution greater
than 2 given the current sample size for dichotomous trait and similarly for the
quantitative trait (**Figure S12**). Principal component analysis of the patients
suggests little genetic differentiation (**Figure S13-14**).
We tested all the QC-passed 19.6 million bi-allelic variants for
association with each of three traits in a logistic or linear regression model that
includes gender, age, and the top 20 PC axes as covariates. The global
distribution of resulting p-values was very close to the null expectation
(λ=0.996-1.1, **Figure S15**) indicating that stratification was adequately
controlled. The most significant SNP rs6020298 is located in the intron of a
read-through transcript *TMEM189-UBE2V1* in the 20q13.13 region. (**Figure 3A-**
B). The rs6020298 (hg38 chr20:50152518, A allele frequency severe vs non-
severe: 0.59 vs 0.45) marks a suggestive significant association signal for both
the Severe and Mild binary trait (logistic regression p=4.1e-6, OR=1.2) and the
quantitative measurement of the severity score (linear regression p=1.1e-6,
beta=0.35) . SNPs in linkage disequilibrium with rs6020298 (r^2>0.8) also affects
the gene *UBE2V1* and *TMEM189* (**Figure 4A**). UBE2V1 encodes the ubiquitin-
conjugating enzyme E2 variant 1. Both the UBE2V1 and TMEM189-UBE2V1
have been involved in the interleukin-1 (IL-1) signaling pathway[45] and
suggested to work together with TRIM5 to promotes innate immune signaling[46].
IL-1 is elevated in COVID-19 patients especially the severe and critical patients
who suffer from the cytokine storm and severe inflation[47]. Clinical trial using IL-
1 blockade on critical patients results in an improvement in respiratory function
in 72% of the patients[48]. The lead SNP rs6020284 has a close to 0.5 minor
allele frequency among the worldwide populations except for the African
population (AF=0.13) (**Figure 4B**). It is also an eQTL for *LINC01273*, *TMEM189*
among several tissues including the lung where the risk A allele increases the
TMEM189 and LINC01273 expression in several tissues (**Figure S16**). This
may indicate that an inborn evaluated TMEM189 expression in the patients
which promotes IL-1 signaling and may predispose the patients towards a
poorer outcome against the COVID-19 infection. However, given the limited
sample size in this study and that the intermediate pathway between TMEM189
and IL-1 production is still unclear, more replication and functional validation
efforts should be made to re-evaluate this association signal. Notably, the
TMEM189-UBE2V1 locus has been associated with monocyte percentage of
leukocytes and granulocyte percentage of myeloid white cells[49]. Nonetheless,
we didn't observe nominal association (p<0.05) at the lead SNP rs6020298 with
all the sixty-four laboratory assessments among the patients (**Figure 4C**).
Therefore, the observed signal is not supposed to be confounded by individual
variability on blood cell types. There is no strong genetic association with the
disease durations **(Figure 3C).**

We further perform optimal SKAT gene-based association test on the
functional variants including a total of 99,166 missense and loss of function
variants that were predicted to have high or moderate impacts by variant effect
predictor among the patients. The *NOA1* gene tend to higher mutation burden
in the severe group (P= 8.1e-07) (**Figure 3D**). This gene encodes the GTPase
that functions in the mitochondrion and has been associated with platelet count
and leukocyte count[45]. We didn't identify other genes that are genome-wide
significantly associated with the severity score or the disease duration (**Figure3
E-F**).
312
HLA gene alleles associated with severity in the COVID-19 patients
Manifestation of numerous infectious diseases are closely related to the genetic
variants across the major histocompatibility complex (MHC) genes, i.e. the
human leukocyte antigen (HLA) genes, which play an essential role in
presenting the antigen determinant epitopes from the pathogens to the T cell or
B cell to activate the host immune response[50,51]. In the 2003 severe acute
respiratory (SARS) outbreak, caused by the SARS coronavirus (SARS-CoV)
related to SARS-CoV-2, the HLA-B*46:01 was reported to be associated with
infection severity in East Asian patients[25]. Herein, we investigated the genetic
effect from HLA genes on the COVID-19 patient severity. We re-aligned all the
reads mapped to the eight HLA haplotypes in the human reference genome
(GRCh38) and all the unaligned reads and typed the three class I HLA genes
(A, B, C) and four class II HLA genes (DPB1, DQA1, DQB1, DRB1) using the
xHLA[52] and the SOAP-HLA approach[53]. 4-digit haplotyping resolution was
achieved for 99% of the patients for all the genes except for DQA1 where three
patients were only typed to the 2-digit resolution. We observed zero mendelian
error rate for the typing results using the family members involved in the study.
We investigated whether some HLA alleles may significantly differ between the
broadly defined severe (severe and critical, N=69) and mild (asymptomatic, mild
and moderate, N=215) groups of unrelated patients using a logistic regression
with age, gender and the top 20 principal components as covariates. The
frequency comparison between the severe and mild groups for total 30 HLA-A,
51 HLA-B, 28 HLA-C, 20 DPB1, 21 DQA1, 16 DQB1 and 32 DRB1 alleles were
displayed in **Figure 4 and Table S2**. Among the class I HLA genes, C*14:02
(severe 8.7% vs mild 4.6%, OR=4.7, P=3e-3), B*51:01 (severe 10.1% vs mild
5.8%, OR=3.3, P=7e-3), A*11:01 (severe 29.7% vs 26.2%, OR=2.3, P=8.5e-3)
are the top three most significant alleles between the two groups that
predispose the patients entering the severe stage **(Table 1)**. The HLA-A*11:01,
B*51:01 and C*14:02 is in strong linkage equilibrium with each other and thus
represents one haplotype. This haplotype has an average allele frequency 2.4%
- 3.6% among the Chinese populations according to the HLA Allele Frequency
Net Database[54]. In our study, we find that this haplotype is more prevalent in
the severe patients compared with the mild patients.
Notably, although B*46:01 has been suggested to present the fewest
SARS-CoV and SARS-CoV-2 peptides in an in silico analysis[55] and has been
associated with the SARS-CoV in a small sample size association analysis

without correcting demographic and geographic covariates[25], our analysis
doesn't support this allele is associated with the disease severity (OR=0.5,
P=0.15). On the contrary, allele frequency of B*46:01 is less frequent in the
severe patients (10.1%) than among the mild patients (12.8%). Class II HLA
genes is less significantly associated with the disease severity (**Table 1**).
DRB1*14:04 (severe 2% vs mild 0.5%, P=0.01), DRB1*01:01 (severe 2.2% vs
0.5%), DQA1*01:01 (severe 2.9% vs 0.9%) are the top three risk alleles while
DPB1*03:01 (severe 0.7% vs mild 4.5%) and DRB1*12:01 (severe 2.2% vs mild
3.7%) might display a protective effect.
358
Comparison with general population for potential genetic contribution to
SARS-CoV-2 infection susceptibility
Our study till now has been restricted in the infected patients to understand
genetic contribution to patient severity. Mapping genes related to infection
susceptibility is more difficult. The ideal design commands a comparison
between people who are exposed or not exposed to the pathogen. This is
hard to meet because early detection and isolation of infected patients are the
primary containment strategies against an outbreak[56]. Therefore, we choose
another approach to investigate genetic susceptibility by comparing the 284
unrelated hospitalized patients (the Case) with two general populations
including 301 Chinese individuals in 1000 genome project[36] (the Control I) and
665 individuals recruited from the Chinese Reference Panel program (CNPR,
manuscript in preparation) that were not infected by COVID-19 (the Control II).
Control I and Control II differ in terms of the similarity of the adopted
sequencing protocol compared to the Case. All the technical components are
almost the same between the Case and Control 2 except for sequencing
depth (case 46x versus control 2 30x). On the other hand, various factors are
different between the case and control 1, including types of sample (case
fresh blood versus control 1 cell line), sequencing technology (case MGI's
nanoball sequencing versus control 1 Illumina sequencing), sequencing read
cycles (case 100bp versus control 1 150bp) and the sequencing depth (case
ave 46x versus ave 7x). Study like this can reveal genetic difference between
the infected population and the general population if any and if not, can
instruct on what caution should be taken when comparing the disease cohorts
versus the general in the whole genome sequencing context.
We analyzed the data carefully by jointly genotype the samples from their
individual gvcf files using the GATK best practices[39] instead of simply merging
the population vcf files of the case and the control. Principle component analysis
indicates that population structure is the dominant confounding factor and
sequencing induced batch effects were difficult to identify in the PCs (**Figure
S17**, **Figure S18**). we conducted both single variant and gene-based
association tests for the two case-control data sets using the top 20 PCs,
gender and age (age was not available for 1KGP samples but was used for the
CNPR) as covariates. Surprisingly, in the single association test for the high
and moderate impact variants, many variants in the HLA region display
significant associations between the COVID-19 patients and the 1KGP Chinese

(**Figure 6A**) even though the inflation was seemingly adequately controlled
(**Figure S19)**. In the gene-based association test, we observed significantly
different mutation burdens in the immunoglobulin loci (**Figure 6B**). However,
this is not replicated when we compared the COVID-19 patients with the 665
CNRP individuals (**Figure 6C-D**). Therefore, we inferred that the association
signals between the 1KGP and the COVID-19 patients were probably due to
sequencing batch effects. As the fresh blood of an infected individual contains
numerous somatic mutated B-cells, patients tend to accumulate more mutations
in the immunoglobulin genes[57]. As many studies try to directly compare the
allele frequency between the general population and the COVID-19 patients[30,32],
our discoveries remind us of the necessity for re-evaluation of the significant
hits given distinct experimental protocol for case and control.
In the single variant association test between the COVID-19 patients and
the CNPR who were sequenced using the same experimental protocol and
were laboratory PCR tested negative, we identified genome-wide significant
associated signals tagged by a novel missense variant (Patient T allele
frequency=0.34, CNPR T_AF=0.14, OR=18, P=4,7e-17) in *MUC2*; a missense
variant rs200584390 (Patient G allele frequency=0.31, CNPR G_AF=0.09,
OR=9.29, P=1.5e-13) in *RIMBP3* and a missense variant rs200975425 (Patient
T allele frequency=0.24, CNPR T_AF=0.39, OR=5.4, P=9.4e-10) in *GOLGA8B*
(**Figure 6C**). Gene-based association test also indicates that *RIMBP3* and
GOLGA8B are different between the patients and the CNPR (**Figure 6D**).
Those discoveries require further replication and interpretation when more
sequencing data for patients and for general populations are generated
worldwide[33].
420
421

Discussion
We have conducted the first genetic association study for the COVID-19
severity and SARS-CoV-2 infection susceptibility by study the genome and
clinical outcome of 332 patients in a designated infectious disease hospital in
Shenzhen City. Instead of using the microarray or the exome genome
sequencing, we have carried out high-depth whole genome sequencing and
analysis for the patients to obtain the greatest possible power given a small
sample size available so far. The study design enables the detection of very
rare and private functional variants for the patients[58] and ensures that all the
potential causal variants are directly assayed to compensate the loss of power
due to poor linkage disequilibrium between the assayed and the causal
variants[59].
We revealed that the disease progression after the SARS-CoV-2
infection is a complex event rather than be explained by a monogenic model.
The severe and critical patients do not carry causal monogenic variants related
to the disease severity in their genome. We identified that the missense variant
rs12329760 in *TMPRSS2* is less frequent among the critical patients compared
to the rest of the patients and the general population. This variant results in an
alteration of the valine to the methionine at the 197th amino acids (p.Val197Met)

has been predicted to decrease the TMPRSS2 protein stability and ACE2
binding[44]. On the other hand, our study using Chinese samples doesn't support
the assumption[30] that host genetic factors in the essential SARS-CoV receptor
ACE2 and some other genes involved in the host pathogen interaction network
may play a role in determining the patient's severity or susceptibility.

In the genome-wide association analysis, a gene locus around
TMEM189-UBE2V1 displayed suggestively association with COVID-19 severity.
This gene locus contains genes such as *UBE2V1* and *TEMEM189-UBE2V1*
that are known to function in the interleukin-1 signaling pathway[45,46]. The lead
SNP rs60220284 is an eQTL where the risk allele A increases the gene
expression of genes within the locus[60] and is more prevalent in the severe and
critical patients. While COVID-19 severe patients demonstrate elevated IL-1
compared to the mild patients and the general population[47], our study suggests
potential correlation between genetic variability in this gene and the disease
severity.

Notably, the HLA-A*11:01, B*51:01 and C*14:02 alleles are significantly
more prevalent in the severe and critical severe patients compared to the mild
and the moderate patients after careful control of population structure and
demographic characters such as age and gender. The three alleles are in
linkage disequilibrium with each other and has been previously reported to have
a 2-3% population allele frequency in Dai and Jinpo minorities in China[54] and
the B*51:01 has been previously linked to the Behcet's disease[61], a kind of
rheumatic disease. We were not able to access the role of HLA-B*46:01, as it's
predicted as the worst presenting HLA alleles to the SARS-CoV-2 proteome[55]
and has been previously linked to the SARS 2003 outbreak[25].

Surprisingly, genome-wide association study using the COVID-19
patients as case and the 1000 genome Chinese population as control suggest
an enrichment of significantly associated signals in the HLA region and mutation
burden in the immunoglobulin genes. Nonetheless, this is not replicated when
we compared the patients to another independent Chinese population. A lot of
efforts in the genetic field have been made and there may be more in the future
to investigate genetic susceptibility of the SARS-COV-2 infection by directly
comparing two or more general populations with the COVID-19 patients[32,33],
cautions should be taken to properly control the batch effects. Replication is
essential and perhaps a joint-analysis effort can rule out the real signals from
the false delusion.

Some limitations of the study should be noted. Power analysis indicates
that sample size of around 300 is barely sufficient to identify genome-wide
significant genetic variants with minor allele frequency greater than 0.2 and
odds ratio greater than 1.8 given type I error rate 0.05. The small sample size
may also result in false positives. In addition, although the study of hospitalized
patients in a designated hospital includes all severe patients, the design has a
limited presentation of the asymptomatic patients (7.5%) which ratio has been
estimated to be 30.8% (95% confidence interval 7.7-53.8%)[62]. Given that RT-
PCR test and the seroprevalence immunoglobulin M and G antibody tests
targeting the SARS-CoV-2 has been widely adopted in China and around the

globe, it will be important to identify and study the extreme asymptomatic patients to understand the host factors contributing to a good control of the viral infection.

   As we and the others are continuing to recruit patients and data in China and around the world to understand the genetic background, this work represents the first genetic study on the Chinese hospitalized patients where high quality sequencing data were generated and systematic analysis on the genomic and clinical data were conducted. Our results highlight several genetic factors involved in the immune responses including genes involved in the viral entry in the host cells, genes related to immune responses and the HLA alleles. This work is also an initial start to guide study design regarding the selection of samples, the genetic assay approach, the bioinformatics and the statistical genetic analysis for COVID-19 as well as other infection and complex disease. The publicly available summary statistics will encourage international collaborative efforts to understand the host-pathogen interaction and to contain the COVID-19 outbreak.

Acknowledgements
The study was supported by National Natural Science Foundation of China (31900487), Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011) and China National GeneBank (CNGB). We would like to acknowledge Fan Zhang from Illumina, Zilong Li and Kang Fang, Defu Xiao from BGI, Xinjun Zhang from University of California, Los Angeles, Emilia Huerta-Sanchez from Brown University and Rasmus Nielsen from University of UC Berkeley for helpful discussions of the results and advice.

Author contributions
Conceptualization, L.L, X.J., Q. H., S. Liu, S.H.; Methodology, J.S. S. Liu, Y.Z., X.T.;Formal Analysis, S.H., Y.Z., X.Q., Zhi.L., P.L., Y.H., R.L., X.T., Y.B., S. Liu; Resources, F.W., R.G., C.L,W.X., Zhi.L, Q.T. R.C. X.L, X.Z., G.D.; Data Curation, S. Liu , F.W., R.G., C.L; Writing – Original Draft, S. Liu; Writing – Review & Editing, All; Supervision, X.X.,J.W.,H.Y.; Project Administration, X.J., S.H., S. Liu, and F.C.; Funding Acquisition, F.W., X.J. and S. Liu.

Material and Methods

Patient recruitment and definition of phenotypes
A total of 332 patients were recruited from Jan 11th 2020 to Apr 2020 in Shenzhen Third People's Hospital, the only referral hospital in Shenzhen City, China[34]. All were confirmed with SARS-COV-2 infection using real-time reverse-transcriptase– polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The demographic, epidemiological, clinical and laboratory assessments were extracted from the electronic medical records of the patients. This study was approved by the ethics commissions of the Shenzhen Third People's Hospital Ethics Committee with a waiver of informed consent. According to the 5th edition of the national treatment guideline of

COVID19 in China and the Chinese CDC criteria[6], the patients were diagnosed as asymptomatic, mild, moderate, severe and critically severe according to the most severe stage they experienced during the disease course. The asymptomatic, mild and the moderate groups of patients do not experience pneumonia. When meeting any one of the following criteria, 1) RR>30 2) Oxygen level < 93% 3) PaO2/FiO2 < 300 mmHg 4) disease progression greater than 50% area in CT scan, a patient is categorized as severe patients. Patients experienced one of the following 1) respiratory failure and requires mechanical ventilation 2) shock 3) complicated by failure of other organs and requires intensive care monitoring were classified as critically severe.

Assignment of severity score to each patient

A machine learning XGBoost-based model was developed to predict ordinal severity scores using patients' phenotype data of 64 laboratory test results[63]. We first filtered out the laboratory test items of which at least 50% of patients did not have any recordings. The remaining 52 laboratory test items with missing values were further imputed by missForest algorithm[64]. The missForest is a nonparametric method to impute missing values using random forest model in an iterative fashion. Then the originally ordered severity levels of asymptomatic, mild, moderate, severe and critical were assigned integer values of 1, 2, 3, 4 and 5, respectively. The numeric representations retained the ordinal levels of severity. We applied the reduction framework mentioned in Li et al[65], where the ordinal regression was reduced to binary classification. The reduction framework of extended binary classification was then integrated within XGBoost model. Moreover, we selected the most predictive laboratory test items using SHAP (SHapley Additive exPlanations) algorithm[66] . The SHAP is a game theoretic approach to explain the output of a given machine learning model using Shapley values from game theory and their related extensions. We finally trained the XGBoost-based ordinal regression model using the selected laboratory test items. As a result, the prediction outcome produced by the final model was typically a real number reflecting severity level that was used in the downstream analysis. We used 100 base estimators for missForest, maximum iteration of 10, and the criterion was mean squared error. For the XGBoost-based ordinal regression model, we used 500 base estimators and learn rate of 0.5. In general, the hyper-parameters of models in this study were chosen by combining grid search of 5-fold cross validation and manual tuning.

DNA extraction, library construction and deep whole genome sequencing

Genomic DNA was extracted from frozen blood samples of the 332 patients using Magnetic Beads Blood Genomic DNA Extraction Kit (MGI, Shenzhen, China). At least 0.5μg was obtained for each individual and used to create WGS library, which insert sizes 300-500bp for paired-end libraries according to the BGI library preparation pipeline. Sequencing was conducted on the DNBSEQ platform (MGI, Shenzhen, China) to generate 100bp paired-end reads.

Genome alignment and variant detection

We used Sentieon Genomics software (version: sentieon-genomics-201911) to perform genome alignment and variant detection[67]. Analysis pipeline were built according to the recommendation in the Broad institute best practices described in https://gatk.broadinstitute.org/hc/en-us/sections/360007226651-Best-Practices-Workflows. Sequencing reads were mapped to hg38 reference genome using BWA algorithm. For each sample, after remove duplicates, Indel realignment and base quality score recalibration (BQSR), SNP and short Indel variants were detect using the Sentieon Haplotyper algorithm with option --emit_mode gvcf to generate an individual GVCF file. Then the GVCF files for all samples were subjected to Sentieon GVCFtyper algorithm to perform joint variant calling.

Variant Quality Score Recalibration and Filtration

Variant Quality Score Recalibration were perform using Genome Analysis Toolkit (GATK version 4.1.2). Known variant files were downloaded from the GATK bundle. For indel recalibration, we used Mills_and_1000G_gold_standard indels as the positive training and true set. For SNP recalibration, we used hapmap_3.3, 1000G_omni2.5, and 1000G_phase1.snps as positive training sets, hapmap_3.3 as true set, and dbSNP_v146 as the known set. The metrics DP, QD, MQRankSum, ReadPosRankSum, FS, SOR were used in the recalibration process. The truth-sensitivity-filter-level were set to 99.0 for both the SNPs and the Indels. Finally, variants with quality score >= 100 were selected for further analysis.

Familial relationship and population structure analysis

PLINK (v1.9)[68] and KING (v2.1.5)[69] was applied to detect the kinship relatedness between each pair of the individuals. 48 patients from 16 families were detected as related to each other. For several allele frequency-based approach, we exclude the related patients and thus the sample size was restricted to 284. PCA was performed using a subset of autosomal bi-allelic SNPs on the unrelated patients using PLINK (v1.9). The PC-AiR module (Principal components analysis in related samples) in the Genesis R package was used to conduct PCA analysis for the 332 patients including the related family members. Several restrictions were employed to select the final 614,963 SNPs for PCA analysis, including minor allele frequency (MAF) ≥ 1% (common and low-frequency variants), genotyping rate ≥ 90%, Hardy-Weinberg-Equilibrium (HWE) P > 0.000001, and removing one SNP from each pair with r2 ≥ 0.5 (in windows of 50 SNPs with steps of 5 SNPs).

Genotype-phenotype association analysis

We have applied both the rvtest[70] and the SAIGE[71] approaches to carry out logistic regression, linear regression, burden test, the sequence kernel analysis test (SKAT) and the optimal SKAT-O algorithm for the genotype-phenotype association tests using the default parameters. For all the association tests, we have used the gender, the age and the top 20 principal components from the

principal component analysis as the covariates. Exception is for the GWAS between the 1KGP and the COVID-19 patients as age is not available for the 1KGP data set. Independent loci were defined as significant variants clustered in a 1Mbp window. The lead SNP was defined as the SNP in the 1Mbp window that has most significant, i.e., smallest p value. The genomic inflation factor, GC lambda, attenuation ratio, LD score regression intercept and the SNP heritability were estimated using the LD score regression approach [72]. The qqman R package was applied to generate the manhattan and qqplot. We defined genome-wide significance for single variant association test as 5e-8, suggestive significance as 1e-5 and for gene-based association test as 1e-6.

HLA typing

When performing HLA typing, we first extracted reads which aligned to HLA region of GRCh38 and unmapped reads from individual bam files. Then using xHLA algorithm[23] typing HLA class I(A B C gene) and II(DRB1 DQB1 DPB1) genes. DQA1 gene was typed using SOAP-HLA algorithm[53] for xHLA does not include this gene. We performed the association analysis between HLA types and the binary severe and mild groups using PLINK (version 1.90) using a logistic regression model, adjusted for age, gender and top 20 PCs.

Data availability

The data that support the findings of this study, including the allele frequency for the five groups of patients at all the 20 million detected genetic variants and the genome-wide association test summary statistics have been deposited in CNSA (China National Genebank Sequence Archive) in Shenzhen, China with accession number CNP0001107 (https://db.cngb.org/cnsa/).

Reference

1.   Johnson, N. P. A. S. & Mueller, J. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. *Bull. Hist. Med.* (2002). doi:10.1353/bhm.2002.0022

2.   Zhu, N. *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* (2020). doi:10.1056/NEJMoa2001017

3.   John Hopkins University and Medicine. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. *John Hopkins Coronavirus Resource Center* (2020).

4.   Jiang, S., Du, L. & Shi, Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerging Microbes and Infections* (2020). doi:10.1080/22221751.2020.1723441

5.   Shi, Z. & Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. *Virus Res.* (2008). doi:10.1016/j.virusres.2007.03.012

6.   Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA* (2020). doi:10.1001/jama.2020.2648

7.   Kenney, A. D. *et al.* Human Genetic Determinants of Viral Diseases. *Annu.*
Rev. Genet. (2017). doi:10.1146/annurev-genet-120116-023425
8.   Guan, W. *et al.* Clinical characteristics of coronavirus disease 2019 in China.
N. Engl. J. Med. (2020). doi:10.1056/NEJMoa2002032
9.   Fu, L. *et al.* Clinical characteristics of coronavirus disease 2019 (COVID-19) in
China: A systematic review and meta-analysis. *J. Infect.* (2020).
doi:10.1016/j.jinf.2020.03.041
10. Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in
China. *N. Engl. J. Med.* (2020). doi:10.1056/NEJMoa2002032
11. The epidemiological characteristics of an outbreak of 2019 novel coronavirus
diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi* (2020).
doi:10.3760/cma.j.issn.0254-6450.2020.02.003
12. Qin, C. *et al.* Dysregulation of immune response in patients with COVID-19 in
Wuhan, China. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa248
13. Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-
CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
observational study. *Lancet Respir. Med.* (2020). doi:10.1016/S2213-
2600(20)30079-5
14. Nishiura, H. Backcalculating the Incidence of Infection with COVID-19 on the
Diamond Princess. *J. Clin. Med.* (2020). doi:10.3390/jcm9030657
15. Hu, Z. *et al.* Clinical characteristics of 24 asymptomatic infections with COVID-
19 screened among close contacts in Nanjing, China. *Sci. China Life Sci.*
(2020). doi:10.1007/s11427-020-1661-4
16. Fellay, J. *et al.* Common genetic variation and the control of HIV-1 in humans.
PLoS Genet. (2009). doi:10.1371/journal.pgen.1000791
17. Fellay, J. *et al.* A whole-genome association study of major determinants for
host control of HIV-1. *Science (80-.).* (2007). doi:10.1126/science.1143767
18. Pereyra, F. *et al.* The major genetic determinants of HIV-1 control affect HLA
class I peptide presentation. *Science (80-.).* (2010).
doi:10.1126/science.1195271
19. Kamatani, Y. *et al.* A genome-wide association study identifies variants in the
HLA-DP locus associated with chronic hepatitis B in Asians. *Nat. Genet.*
(2009). doi:10.1038/ng.348
20. Ge, D. *et al.* Genetic variation in IL28B predicts hepatitis C treatment-induced
viral clearance. *Nature* (2009). doi:10.1038/nature08309
21. Schulert, G. S. *et al.* Whole-exome sequencing reveals mutations in genes
linked to hemophagocytic lymphohistiocytosis and macrophage activation
syndrome in fatal cases of H1N1 influenza. *J. Infect. Dis.* (2016).
doi:10.1093/infdis/jiv550
22. Wang, Z. *et al.* Early hypercytokinemia is associated with interferon-induced
transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection.
Proc. Natl. Acad. Sci. U. S. A. (2014). doi:10.1073/pnas.1321748111
23. Everitt, A. R. *et al.* IFITM3 restricts the morbidity and mortality associated with
influenza. *Nature* (2012). doi:10.1038/nature10921
24. Yang, X. *et al.* Interferon-inducible transmembrane protein 3 genetic variant
rs12252 and influenza susceptibility and severity: A meta-analysis. *PLoS One*
(2015). doi:10.1371/journal.pone.0124985
25. Lin, M. *et al.* Association of HLA class I with severe acute respiratory
syndrome coronavirus infection. *BMC Med. Genet.* (2003). doi:10.1186/1471-
2350-4-9

26. Ching, J. C. *et al.* Significance of the Myxovirus Resistance A (MxA) Gene
−123C>A Single-Nucleotide Polymorphism in Suppressed Interferon β
Induction of Severe Acute Respiratory Syndrome Coronavirus Infection. *J.*
Infect. Dis. **201**, 1899–1908 (2010).

27. Kachuri, L. *et al.* The landscape of host genetic factors involved in infection to
common viruses and SARS-CoV-2. *medRxiv* (2020).
doi:10.1101/2020.05.01.20088054

28. Williams, F. M. *et al.* Self-reported symptoms of covid-19 including symptoms
most predictive of SARS-CoV-2 infection, are heritable. *medRxiv* (2020).
doi:10.1101/2020.04.22.20072124

29. Zhao, J. *et al.* Relationship between the ABO Blood Group and the COVID-19
Susceptibility. *medRxiv* (2020). doi:10.1101/2020.03.11.20031096

30. Cao, Y. *et al.* Comparative genetic analysis of the novel coronavirus (2019-
nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* **6**, 4–
7 (2020).

31. Bhattacharyya, C. *et al.* Global Spread of SARS-CoV-2 Subtype with Spike
Protein Mutation D614G is Shaped by Human Genomic Variations that
Regulate Expression of TMPRSS2 and MX1 Genes. *bioRxiv* (2020).
doi:10.1101/2020.05.04.075911

32. Renieri, A. *et al.* ACE2 variants underlie interindividual variability and
susceptibility to COVID-19 in Italian population. *medRxiv* (2020).
doi:10.1101/2020.04.03.20047977

33. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role
of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus
pandemic. *Eur. J. Hum. Genet.* (2020). doi:10.1038/s41431-020-0636-6

34. Cai, Q. *et al.* COVID-19 in a designated infectious diseases hospital outside
Hubei Province, China. *Allergy Eur. J. Allergy Clin. Immunol.* (2020).
doi:10.1111/all.14309

35. Darbeheshti, F. & Rezaei, N. Genetic predisposition models to COVID-19
infection. *Medical Hypotheses* (2020). doi:10.1016/j.mehy.2020.109818

36. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**,
68–74 (2015).

37. Lundberg, S. M. *et al.* From local explanations to global understanding with
explainable AI for trees. *Nat. Mach. Intell.* (2020). doi:10.1038/s42256-019-
0138-9

38. Jiang, X. *et al.* Towards an Artificial Intelligence Framework for Data-Driven
Prediction of Coronavirus Clinical Severity. *Comput. Mater. Contin.* (2020).
doi:10.32604/cmc.2020.010691

39. Depristo, M. A. *et al.* A framework for variation discovery and genotyping using
next-generation DNA sequencing data. *Nat. Genet.* (2011). doi:10.1038/ng.806

40. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* (2016).
doi:10.1186/s13059-016-0974-4

41. Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes
reveals the spectrum of loss-of-function intolerance across human protein-
coding genes. *bioRxiv* (2019). doi:10.1101/531210

42. Collins, R. L. *et al.* An open resource of structural variation for medical and
population genetics. *bioRxiv* (2019). doi:10.1101/578674

43. Dai, W. *et al.* Whole-exome sequencing identifies MST1R as a genetic
susceptibility gene in nasopharyngeal carcinoma. *Proc. Natl. Acad. Sci. U. S.*
A. (2016). doi:10.1073/pnas.1523436113

44. Sharma, S. *et al.* ACE2 Homo-dimerization, Human Genomic variants and
Interaction of Host Proteins Explain High Population Specific Differences in
Outcomes of COVID19. *bioRxiv* (2020). doi:10.1101/2020.04.24.050534
45. Stelzer, G. *et al.* The GeneCards suite: From gene data mining to disease
genome sequence analyses. *Curr. Protoc. Bioinforma.* (2016).
doi:10.1002/cpbi.5
46. Pertel, T. *et al.* TRIM5 is an innate immune sensor for the retrovirus capsid
lattice. *Nature* (2011). doi:10.1038/nature09976
47. Shi, Y. *et al.* COVID-19 infection: the perspectives on immune responses. *Cell*
Death and Differentiation (2020). doi:10.1038/s41418-020-0530-3
48. Cavalli, G. *et al.* Interleukin-1 blockade with high-dose anakinra in patients with
COVID-19, acute respiratory distress syndrome, and hyperinflammation: a
retrospective cohort study. *Lancet Rheumatol.* (2020). doi:10.1016/s2665-
9913(20)30127-2
49. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide
association studies, targeted arrays and summary statistics 2019. *Nucleic*
Acids Res. (2019). doi:10.1093/nar/gky1120
50. Hammer, C. *et al.* Amino acid variation in HLA class II proteins is a major
determinant of humoral response to common viruses. *Am. J. Hum. Genet.*
(2015). doi:10.1016/j.ajhg.2015.09.008
51. Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies
identify susceptibility loci for multiple common infections. *Nat. Commun.*
(2017). doi:10.1038/s41467-017-00257-5
52. Xie, C. *et al.* Fast and accurate HLA typing from short-read next-generation
sequence data with xHLA. *Proc. Natl. Acad. Sci. U. S. A.* (2017).
doi:10.1073/pnas.1707945114
53. Cao, H. *et al.* An Integrated Tool to Study MHC Region: Accurate SNV
Detection and HLA Genes Typing in Human MHC Region Using Targeted
High-Throughput Sequencing. *PLoS One* (2013).
doi:10.1371/journal.pone.0069388
54. Gonzalez-Galarza, F. F. *et al.* Allele frequency net database. in *Methods in*
Molecular Biology (2018). doi:10.1007/978-1-4939-8546-3_4
55. Nguyen, A. *et al.* Human leukocyte antigen susceptibility map for SARS-CoV-
2. *J. Virol.* (2020). doi:10.1128/jvi.00510-20
56. Lai, S. *et al.* Effect of non-pharmaceutical interventions to contain COVID-19 in
China. *Nature* (2020). doi:10.1038/s41586-020-2293-x
57. Ju, B. *et al.* Potent human neutralizing antibodies elicited by SARS-CoV-2
infection. *bioRxiv* 2020.03.21.990770 (2020). doi:10.1101/2020.03.21.990770
58. Rashkin, S., Jun, G., Chen, S. & Abecasis, G. R. Optimal sequencing
strategies for identifying disease-associated singletons. *PLoS Genet.* (2017).
doi:10.1371/journal.pgen.1006811
59. Wainschtein, P. *et al.* Recovery of trait heritability from whole genome
sequence data. *Yearb. Paediatr. Endocrinol.* (2019). doi:10.1530/ey.16.14.15
60. Carithers, L. J. & Moore, H. M. The Genotype-Tissue Expression (GTEx)
Project. *Biopreservation and Biobanking* (2015).
doi:10.1089/bio.2015.29031.hmm
61. Giza, M., Koftori, D., Chen, L. & Bowness, P. Is Behçet's disease a 'class 1-
opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.
Clinical and Experimental Immunology (2018). doi:10.1111/cei.13049
62. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus

infections (COVID-19). *International Journal of Infectious Diseases* (2020).
doi:10.1016/j.ijid.2020.03.020

63. Chen, T. & Guestrin, C. XGBoost: A scalable tree boosting system. in
Proceedings of the ACM SIGKDD International Conference on Knowledge
Discovery and Data Mining (2016). doi:10.1145/2939672.2939785

64. Stekhoven, D. J. & Bühlmann, P. Missforest-Non-parametric missing value
imputation for mixed-type data. *Bioinformatics* (2012).
doi:10.1093/bioinformatics/btr597

65. Li, L. & Lin, H. T. Ordinal regression by extended binary classification. in
Advances in Neural Information Processing Systems (2007).
doi:10.7551/mitpress/7503.003.0113

66. Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model
predictions. in *Advances in Neural Information Processing Systems* (2017).

67. Freed, D. N., Aldana, R., Weber, J. A. & Edwards, J. S. The Sentieon
Genomics Tools - A fast and accurate solution to variant calling from next-
generation sequence data. *bioRxiv* (2017).

68. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger
and richer datasets. *Gigascience* **4**, 7 (2015).

69. Manichaikul, A. *et al.* Robust relationship inference in genome-wide
association studies. *Bioinformatics* (2010). doi:10.1093/bioinformatics/btq559

70. Zhan, X., Hu, Y., Li, B., Abecasis, G. R. & Liu, D. J. RVTESTS: An efficient
and comprehensive tool for rare variant association analysis using sequence
data. *Bioinformatics* (2016). doi:10.1093/bioinformatics/btw079

71. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample
relatedness in large-scale genetic association studies. *Nat. Genet.* (2018).
doi:10.1038/s41588-018-0184-y

72. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
polygenicity in genome-wide association studies. *Nat. Genet.* (2015).
doi:10.1038/ng.3211

862
863
Figure 1. Clinical and laboratory assessments of the recruited 332 COVID-19
patients. (A) number of samples belong to the five categories (B) top 20 features that
classify the patient categories in the machine learning trained model (C) age
distribution for the five categories of patients (D) distribution of disease duration, i.e.
the duration between the disease onset and the first negative RT-PCR test among the
five groups of patients (E) gender distribution for the five categories of patients by age
(F) distribution of the proportion of patients with or without medical comorbidities
among the five categories of patients by age.
872
873

875
876
Figure 2. Deep whole genome sequencing and genetic variation among the
patients. A) Sequencing depth distribution B) Proportions and numbers of types (SNP,
Indel) of genetic variants identified from the patients C) Proportions and numbers of
functional consequences of the genetic variants among the patients D) comparison of
loss of function variation burden for SNP, small insertions and deletions between the
severe and the non-severe patients E) Single variation association test for loss of
function mutation burden between the severe and non-severe patients F) allele
frequency distribution for all the missense and loss of function variants present in
ACE2 and *TRMPSS2* genes.
886
887

Figure 3. Genetic loci associated with patient severity (A)-(C) Single variant and association test for three severity traits. (A) Severe and critical severe groups versus the rest of the non-severe groups. (B) Severity score assessed by laboratory test measurements. (C) the duration from disease onset to recovery (D)-(F) Gene-based association test for three traits.

916
**Figure 4. LD, allele frequency and pleiotropic effects of the *TMEM189-UBE2V1*
signal suggestively associated with COVID-19 patient severity.** A) Locuszoom
plot shows the p-value of the SNPs centering the lead SNP rs6020298 and the
recombination rate. Color of the dots indicate linkage disequilibrium r2 metric. B) Allele
frequency of s6020298 among the 1000 genomes populations. The allele frequency
of the reference and alternative allele is visualized by the geography of genetic
variants browser developed by the university of Chicago. C) P-value of the single
variant genome-wide association test for the sixty-four laboratory assessments at the
lead SNP rs6020298. The P-value of the three traits (Severity, Severity score and
Disease Duration) in Figure 3 were also displayed.

934
935
936
937 **Figure 5. Human leukocyte haplotype allele frequency between severe vs non-**
938 **severe groups.** Comparison for class I HLA genes (top). Comparison for class II HLA
939 genes (bottom). Star indicates significance level in a logistic regression on the allele
940 frequency with age, gender and the top twenty principal components as covariates.
941 *<0.05, **<0.01

956
957
Figure 6. Single variant and gene-based association test between COVID-19
patients and the general populations. (A) single variant association test and (B)
gene-based association test between the unrelated COVID-19 patients (N=284) and
the 1KGP Chinese population (N=301) (C) single variant association test and (D)
gene-based association test between the unrelated COVID-19 patients (N=284) and
the CNRP Chinese population (N=665). Only variants with moderate or high impacts
by variant effect predictor were shown in (A) and (C).

Table 1. Nominal association of HLA allele and severity by logistic rgression

	Severe	Non-severe	OR	SE	P
C*14:02	0.086	0.047	4.75	0.52	0.003028
B*51:01	0.101	0.058	3.38	0.45	0.007017
A*11:01	0.297	0.263	2.33	0.32	0.008512
DRB1*14:04	0.029	0.005	15.1	1.06	0.01027
DRB1*01:01	0.022	0.005	13.7	1.13	0.02034
DPB1*03:01	0.008	0.044	0.09	1.15	0.03669
DQA1*01:01	0.029	0.009	6.05	0.87	0.03947
DRB1*12:01	0.022	0.037	0.18	0.87	0.04478
B*13:02	0.058	0.051	0.27	0.66	0.04935

Severe group indicates severe and critical patients
Non-severe group includes asymptomatic, mild and moderate patients